Table 2 Selected ongoing clinical trials targeting immune checkpoints
From: Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
Clinical trial | Phase | n | Disease | Intervention | Sponsor/collaborators |
|---|---|---|---|---|---|
NCT03630159 | I | 32 | DLBCL | Tisagenlecleucel + pembrolizumab | Novartis |
NCT03620578 | II | 102 | NHL, HGBCL | DA-R-EPOCH induction followed by nivolumab consolidation | Stichting Hemato Oncologie voor Volwassenen Nederland |
NCT03121677 | I | 20 | FL | Nivolumab/poly-ICLC/vaccine/±rituximab | Washington University Bristol Myers Squibb |
NCT03046953 | II | 35 | RR T cell lymphoma | Avelumab | University of Birmingham Bloodwise/ Pfizer/UK |
NCT03003520 | II | 46 | Untreated high-risk DLBCL | Durvalumab + R-CHOP or durvalumab + R-CHOP + lenalidomide | Celgene |
NCT02935361 | I/II | 72 | CMML, MDS, relapsed AML | Guadecitabine and atezolizumab | USC/NCI/Van Andel Research Institute |
NCT02733042 | I/II | 106 | Lymphoma/CLL | Durvalumab as monotherapy, durvalumab + ibrutinib Durvalumab + bendamustine ± rituximab Durvalumab and lenalidomide ± rituximab | Celgene |
NCT02684292 | III | 300 | RR HL | Pembrolizumab vs brentuximab vedotin | Merck Sharp & Dohme Corp. |
NCT02603419 | I | 33 | RR HL | Avelumab | Pfizer |
NCT01896999 | I/II | 189 | RR HL | Brentuximab vedotin and nivolumab ± ipilimumab | NCI |
NCT02951156 | III | 28 | RR DLBCL | Phase I: avelumab/utomilumab/rituximab vs avelumab/utomilumab/azacytidine vs avelumab/rituximab/bendamustine Phase III: any of the above combinations vs. rituximab/bendamustine or rituximab/gemcitabine/oxaliplatin | Pfizer/EMD Serono |
NCT01592370 | I/II | 375 | NHL/HL/MM | Nivolumab monotherapy, nivolumab + lirilumab, nivolumab + ipilimumab, daratumumab vs nivolumab + daratumumab, nivolumab + daratumumab + pomalidomide + dexamethasone vs. nivolumab daratumumab | Bristol Myers Squibb/Janssen |
NCT03390296 | II | 138 | RR AML | Arm A: PF-04518600 Arm B: PF-04518600 + avelumab Arm C: PF-04518600 + azacytidine Arm D: PF-04518600 + utomilumab Arm E: avelumab + utomilumab Arm F: PF-04518600 + azacytidine + avelumab Arm G: gemtuzumab ozogamicin + glasdegib Arm H: glasdegib + avelumab | M.D. Anderson Cancer Center/Pfizer |
LAG-3 and TIM3 | |||||
 NCT03489369 | I | 30 | Metastatic solid tumor and lymphoma | Sym022 (anti-LAG-3) | Symphogen |
 NCT03489343 | I | 48 | Metastatic solid tumor and lymphoma | Sym023 (anti-TIM3) | Symphogen |
 NCT03311412 | I | 102 | Metastatic solid tumor and lymphoma | Sym021 (anti-PD-1) monotherapy or in combination with Sym022 (anti-LAG3) or Sym023 (anti-TIM3) | Symphogen |
 NCT02061761 | I/II | 132 | Hematologic malignancies | BMS 986016 (anti-LAG3) ± nivolumab (BMS-936558) | Symphogen |
 NCT03005782 | I | 546 | Malignancies | REGN3767 (anti-LAG-3 Ab ± REGN2810 (anti-PD-1) | Regeneron Pharmaceuticals/Sanofi |
 NCT03219268 | I | 243 | Solid and hematologic malignancies | MGD013 DART (PD-1 and LAG-3 antibody) | MacroGenics |
CD27 | |||||
 NCT03307746 | I/II | 40 | B cell lymphoma | Varlilumab plus rituximab | Celldex Therapeutics/National Health Service Trust-UK |
 NCT01460134 | I | 90 | CD27+ B and T cell lymphoma, Burkitt’s lymphoma, solid malignancies, CNS lymphoma | Varlilumab | Celldex Therapeutics |
 NCT03038672 | II | 106 | RR aggressive B cell lymphomas | Varlilumab plus nivolumab | NCI |
CD70 | |||||
 NCT03030612 | I/II | 36 | AML and high-risk MDS | ARGX-110 plus azacytidine | Argenx BVBA |
 NCT01813539 | I/II | 100 | Advanced cancers | ARGX-110 | Argenx BVBA |